India accounts for approximately 25 per cent of the world’s β-thalassemia cases, with an estimated 42 million carriers nationwide. Every year, between 10,000 and 15,000 children are born with ...

CHULA VISTA, Calif. — Nothing can prepare you for parenthood, and a local family was not ready to hear their unborn child may die or have life long complications. For Annemarie and Stephen, they were ...

Patients with beta-thalassemia major (also known as Cooley's anemia) have a reduction or absence of beta protein in their hemoglobin, resulting in severe anemia, which requires regular blood ...

An essential factor in distinguishing thalassemia phenotypes is transfusion dependence. While beta-thalassemia major requires life-long blood transfusions for survival, non-transfusion-dependent ...

Thalassemia, a preventable genetic blood disorder, is not merely a medical condition; it is a demographic and social challenge that quietly but relentlessly impacts families, health systems, and ...

Patients who had ruxolitinib added to their prophylactic regimens had lower rates of acute and chronic graft-versus-host disease (GVHD). Ruxolitinib (Jakafi) may be a meaningful prophylactic against ...

Thanks to groundbreaking in-utero blood transfusion technology, what was once a fatal diagnosis in the womb can now result in live births. However, this medical advancement created a new challenge: a ...

Bone marrow transplantation is the only therapeutic option that can eliminate thalassemic disease. Thalassemic patient categories that are prognostically significant for the outcome of marrow ...

On January 21st, the Thalassemia International Federation (TIF) and BGI Genomics jointly hosted an educational webinar focused on thalassemia prevention in high-prevalence regions. The event featured ...